Recovery & repair stack: BPC-157 + TB-500
Support soft-tissue repair between heavy training blocks.
The recovery stack pairs BPC-157 (250–500 mcg daily, subcutaneous, often near the affected area) with TB-500 (2–5 mg twice weekly for 4 weeks, then roughly 2 mg weekly). The two are combined because their mechanisms differ: BPC-157 is studied mainly for local angiogenesis and tendon-to-bone healing, TB-500 for systemic cell migration and actin regulation. Nearly all of the published evidence is animal work — there are no completed controlled human trials for tendinopathy — so treat any protocol you read, including this one, as community practice summarised, not established medicine.
Educational only
This page summarizes published research and community protocols. It is not medical advice, and nothing here is a recommendation to use these compounds. Get baseline bloodwork and work with a licensed clinician first. See our medical disclaimer.
The protocol
| Compound | Typical dose | Frequency | Role |
|---|---|---|---|
| BPC-157 | 250–500 mcg | Daily, subcutaneous, near the affected site | Local angiogenesis and tendon/ligament repair signalling in animal models. |
| TB-500 | 2–5 mg loading, then ~2 mg | 2× weekly for 4 weeks, then once weekly | Synthetic thymosin beta-4 fragment; studied for cell migration and tissue remodelling. |
- Cycle
- 4–6 weeks on, 4 weeks off
- Timing
- No fixed time of day; consistency matters more than clock time
- Route
- Subcutaneous injection; BPC-157 is commonly placed close to the injured area
- Storage
- Reconstituted peptide refrigerated at 2–8 °C and used within the supplier's stated window
- Stack with
- Physiotherapy and progressive loading — not instead of them
Who this stack suits
Best for
- Lifters coming off a heavy block with nagging tendon or joint irritation
- People rehabbing a diagnosed soft-tissue injury alongside physiotherapy
- Anyone who wants recovery support without touching the growth-hormone axis
Not for
- Anyone with an active or historical cancer diagnosis — both compounds are pro-angiogenic
- Competitive athletes subject to WADA testing
- People looking for direct muscle growth; this stack is repair-oriented, not anabolic
What the evidence says
What the research actually shows
BPC-157 has a large rodent literature covering tendon, ligament, muscle and gut healing, with consistent positive findings across groups. What it does not have is a completed randomised controlled trial in humans for musculoskeletal injury, so effect size in people is unknown. TB-500 evidence is thinner still: thymosin beta-4 itself has been studied in human trials for dry eye and pressure ulcers, but the TB-500 fragment sold for injection has no comparable human data.
Why people run them together
The stated rationale is complementary mechanism rather than additive dose: BPC-157 is described as acting locally on new blood-vessel formation and fibroblast behaviour, TB-500 systemically on cell migration. There is no published head-to-head or combination trial, so the pairing is a reasoned guess, not a demonstrated synergy.
What to expect honestly
Users typically report reduced tendon irritation within 2–4 weeks. That timeline overlaps almost exactly with the natural course of deload-plus-rehab, which is why self-reported results are so hard to interpret. Logging pain scores and loading tolerance before you start is the only way to tell one from the other.
Risks and side effects
- None of these compounds are FDA-approved for muscle building, all are WADA-banned in competition, and research-chemical sourcing means purity is never guaranteed.
- Both compounds promote new blood-vessel growth — a theoretical concern with any undiagnosed tumour.
- Injection-site reactions, redness and transient lightheadedness are the most commonly reported effects.
- Sterility matters: unsterile reconstitution or reuse of needles causes abscesses and worse.
Monitoring
Bloodwork to run
- Baseline CBC and a comprehensive metabolic panel before the first dose
- Repeat at the end of each cycle so you have a before-and-after, not a guess
- An imaging or clinical re-assessment of the injury itself, since that is the actual outcome
What to track in DoseRoutine
- Dose, site and time of every injection
- A 0–10 pain or stiffness score for the affected area, once a day
- Loading tolerance — the weight or range of motion you can work through without flare-up
Frequently asked
- How long before BPC-157 and TB-500 start working?
- Community reports usually describe a change in tendon or joint irritation somewhere in weeks 2–4 of a 4–6 week cycle. There is no human trial that establishes an onset time, and the same window is when rest and rehab alone typically start paying off, so track a daily pain score from before you start if you want an answer you can trust.
- Can you run BPC-157 and TB-500 at the same time?
- That is how the stack is normally described: BPC-157 daily throughout, TB-500 loaded twice weekly for the first four weeks and then dropped to a weekly maintenance dose. No published trial has tested the combination in humans, so the pairing rests on non-overlapping proposed mechanisms rather than measured synergy.
- Is BPC-157 legal?
- It is not an approved drug. In the United States the FDA moved BPC-157 off the list of substances eligible for pharmacy compounding in 2023, and it is banned by WADA for athletes in and out of competition. It is sold as a research chemical, which means purity, dose accuracy and sterility vary by supplier and are not independently verified.
- Does this stack build muscle?
- No. Neither compound is anabolic. The argument for using them during a training block is indirect: less tendon pain means more consistent hard sessions, and consistency is what drives hypertrophy. If muscle growth is the goal, the GH pulse stack or straightforward progressive overload is a more honest fit.
Compounds in this stack
Full monographs with doses, evidence quality, interactions and sources.
Other stacks
Keep exploring
Last reviewed 2026-09-22.